p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression

Oncotarget

Volumn 7, Issue 11, 2016, Pages 11785-11802

  Landré, Vivien ^a   Antonov, Alexey ^a   Knight, Richard ^a   Melino, Gerry ^a,b  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cell death; Metastasis; p53 family; Periostin; Temozolomide

Indexed keywords

PROTEIN P73; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; P73 PROTEIN, HUMAN; POSTN PROTEIN, HUMAN; TUMOR PROTEIN P73;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG RESISTANCE; GLIOBLASTOMA CELL LINE; IN VITRO STUDY; METASTASIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; APOPTOSIS; CELL MOTION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL CULTURE; TUMOR INVASION;

APOPTOSIS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; TUMOR CELLS, CULTURED; TUMOR PROTEIN P73;

EID: 84962799595     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7600     Document Type: Article

References (121)

1. Jackson M, Hassiotou F and Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis. 2015; 36:177-185.
2. Chen J, McKay RM and Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012; 149:36-47.
3. Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS and Ahmed AU. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell death and differentiation. 2014; 21:1119-1131.
4. Dickinson A, Yeung KY, Donoghue J, Baker MJ, Kelly RD, McKenzie M and Johns TG. The regulation of mitochondrial DNA copy number in glioblastoma cells. Cell death and differentiation. 2013; 20:1644-1653.
5. Lugli N, Kamileri I and Halazonetis TD. PARP inhibitors and IR join forces to strike glioblastoma-initiating cells. Cell death and differentiation. 2014; 21:192-193.
6. Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A and Abounader R. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell death and differentiation. 2014; 21:720-734.
7. Bageritz J, Puccio L, Piro RM, Hovestadt V, Phillips E, Pankert T, Lohr J, Herold-Mende C, Lichter P and Goidts V. Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell death and differentiation. 2014; 21:929-940.
8. Liu JK, Lubelski D, Schonberg DL, Wu Q, Hale JS, Flavahan WA, Mulkearns-Hubert EE, Man J, Hjelmeland AB, Yu J, Lathia JD and Rich JN. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell death and differentiation. 2014; 21:1325-1339.
9. Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D and Fulda S. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB. Cell death and differentiation. 2014; 21:735-747.
10. Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G and Melchiorri D. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell death and differentiation. 2013; 20:396-407.
11. Leszczyniecka M, Roberts T, Dent P, Grant S and Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacology & therapeutics. 2001; 90:105-156.
12. Li Y, Yin W, Wang X, Zhu W, Huang Y and Yan G. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:13438-13443.
13. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J and Rich JN. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell death and differentiation. 2014; 21:258-269.
14. Cruz FD and Matushansky I. Solid tumor differentiation therapy - is it possible? Oncotarget. 2012; 3:559-567. doi: 10.18632/oncotarget.512.
15. Dotsch V, Bernassola F, Coutandin D, Candi E and Melino G. p63 and p73, the ancestors of p53. Cold Spring Harbor perspectives in biology. 2010; 2:a004887.
16. Dulloo I, Phang BH, Othman R, Tan SY, Vijayaraghavan A, Goh LK, Martin-Lopez M, Marques MM, Li CW, Wang de Y, Marin MC, Xian W, McKeon F and Sabapathy K. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nature cell biology. 2015; 17:511-523.
17. Zambetti GP. Expanding the reach of the p53 tumor suppressor network. Cell death and differentiation. 2014; 21:505-506.
18. Solomon H, Sharon M and Rotter V. Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53beta and p53gamma. Cell death and differentiation. 2014; 21:1347-1349.
19. Soussi T and Wiman KG. TP53: an oncogene in disguise. Cell death and differentiation. 2015; 22:1239-1249.
20. Garufi A, Pucci D and D'Orazi V. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell death & disease. 2014; 5:e1271.
21. Simon HU, Yousefi S, Schmid I and Friis R. ATG5 can regulate p53 expression and activation. Cell death & disease. 2014; 5:e1339.
22. Ci Y, Shi K, An J, Yang Y, Hui K, Wu P, Shi L and Xu C. ROS inhibit autophagy by downregulating ULK1 mediated by the phosphorylation of p53 in selenite-treated NB4 cells. Cell death & disease. 2014; 5:e1542.
23. Evstafieva AG, Garaeva AA, Khutornenko AA, Klepikova AV, Logacheva MD, Penin AA, Novakovsky GE, Kovaleva IE and Chumakov PM. A sustained deficiency of mitochondrial respiratory complex III induces an apoptotic cell death through the p53-mediated inhibition of pro-survival activities of the activating transcription factor 4. Cell death & disease. 2014; 5:e1511.
24. Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H, Zou W and Fang JY. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell death & disease. 2014; 5:e1108.
25. Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A and Boussioutas A. Role of p53 in the progression of gastric cancer. Oncotarget. 2014; 5:12016-12026. doi: 10.18632/oncotarget.2434.
26. Dashzeveg N, Taira N, Lu ZG, Kimura J and Yoshida K. Palmdelphin, a novel target of p53 with Ser46 phosphorylation, controls cell death in response to DNA damage. Cell death & disease. 2014; 5:e1221.
27. Manzl C, Fava LL, Krumschnabel G, Peintner L, Tanzer MC, Soratroi C, Bock FJ, Schuler F, Luef B, Geley S and Villunger A. Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on Caspase-2 or the PIDDosome. Cell death & disease. 2013; 4:e942.
28. Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR and Vadlamudi RK. Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response. Cell death and differentiation. 2014; 21:1409-1418.
29. Phesse TJ, Myant KB, Cole AM, Ridgway RA, Pearson H, Muncan V, van den Brink GR, Vousden KH, Sears R, Vassilev LT, Clarke AR and Sansom OJ. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell death and differentiation. 2014; 21:956-966.
30. Bisio A, Zamborszky J, Zaccara S, Lion M, Tebaldi T, Sharma V, Raimondi I, Alessandrini F, Ciribilli Y and Inga A. Cooperative interactions between p53 and NFkappaB enhance cell plasticity. Oncotarget. 2014; 5:12111-12125. doi: 10.18632/oncotarget.2545.
31. Kim J, Nakasaki M, Todorova D, Lake B, Yuan CY, Jamora C and Xu Y. p53 Induces skin aging by depleting Blimp1+ sebaceous gland cells. Cell death & disease. 2014; 5:e1141.
32. Li L, Ng DS, Mah WC, Almeida FF, Rahmat SA, Rao VK, Leow SC, Laudisi F, Peh MT, Goh AM, Lim JS, Wright GD and Mortellaro A. A unique role for p53 in the regulation of M2 macrophage polarization. Cell death and differentiation. 2015; 22:1081-1093.
33. Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, Young KH, Hu W and Feng Z. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell death and differentiation. 2014; 21:1792-1804.
34. Peuget S, Bonacci T, Soubeyran P, Iovanna J and Dusetti NJ. Oxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation. Cell death and differentiation. 2014; 21:1107-1118.
35. Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X, Wang H, Schlenker EH, Zhang D, Telleria C, Huang L, Chauhan SC and Rezvani K. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell death & disease. 2014; 5:e1118.
36. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB and Liu T. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014; 5:4257-4268. doi: 10.18632/oncotarget.1991.
37. Zhang HH, Li SZ, Zhang ZY, Hu XM, Hou PN, Gao L, Du RL and Zhang XD. Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage. Cell death and differentiation. 2014; 21:1656-1663.
38. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M and De Maria R. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell death and differentiation. 2014; 21:774-782.
39. Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U and Sozzi G. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell death & disease. 2014; 5:e1564.
40. Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, Cescon M, Chieco P, Bolondi L and Gramantieri L. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014; 5:10607-10620. doi: 10.18632/oncotarget.2523.
41. Hoffman Y, Bublik DR, Pilpel Y and Oren M. miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell death and differentiation. 2014; 21:302-309.
42. Ren ZJ, Nong XY, Lv YR, Sun HH, An PP, Wang F, Li X, Liu M and Tang H. Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. Cell death & disease. 2014; 5:e1387.
43. Soutto M, Chen Z, Saleh MA, Katsha A, Zhu S, Zaika A, Belkhiri A and El-Rifai W. TFF1 activates p53 through down-regulation of miR-504 in gastric cancer. Oncotarget. 2014; 5:5663-5673. doi: 10.18632/oncotarget.2156.
44. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, Yang Q, Chan CS and Feng Z. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget. 2014; 5:9106-9117. doi: 10.18632/oncotarget.2379.
45. Marcel V, Fernandes K, Terrier O, Lane DP and Bourdon JC. Modulation of p53beta and p53gamma expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell death and differentiation. 2014; 21:1377-1387.
46. Slatter TL, Hung N, Bowie S, Campbell H, Rubio C, Speidel D, Wilson M, Baird M, Royds JA and Braithwaite AW. Delta122p53, a mouse model of Delta133p53alpha, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell death & disease. 2015; 6:e1783.
47. Becker MS, Schmezer P, Breuer R, Haas SF, Essers MA, Krammer PH and Li-Weber M. The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression. Cell death & disease. 2014; 5:e1000.
48. Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, Zhong X, Rojas Y, Yu Y, Zhao Y, Vasudevan SA, Zhang H, Nuchtern JG, Kim ES, Chen X, Lu F, et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell death & disease. 2014; 5:e1079.
49. Idogawa M, Ohashi T, Sugisaka J, Sasaki Y, Suzuki H and Tokino T. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget. 2014; 5:7540-7548. doi: 10.18632/oncotarget.2272.
50. Landre V, Rotblat B, Melino S, Bernassola F and Melino G. Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget. 2014; 5:7988-8013. doi: 10.18632/oncotarget.2431.
51. Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, Bernassola F, Cavasotto CN, Knight RA, Ciechanover A and Melino G. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell death & disease. 2014; 5:e1203.
52. Yi L, Sun Y and Levine A. Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget. 2014; 5:8924-8936. doi: 10.18632/oncotarget.2441.
53. Zhuang C, Sheng C, Shin WS, Wu Y, Li J, Yao J, Dong G, Zhang W, Sham YY, Miao Z and Zhang W. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-kappaB pathways. Oncotarget. 2014; 5:10830-10839. doi: 10.18632/oncotarget.2521.
54. Weilbacher A, Gutekunst M, Oren M, Aulitzky WE and van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell death & disease. 2014; 5:e1318.
55. Zhang X, Cheng L, Minn K, Madan R, Godwin AK, Shridhar V and Chien J. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget. 2014; 5:11365-11380. doi: 10.18632/oncotarget.2497.
56. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN and Carpizo DR. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget. 2014; 5:8879-8892. doi: 10.18632/oncotarget.2432.
57. Adamovich Y, Adler J, Meltser V, Reuven N and Shaul Y. AMPK couples p73 with p53 in cell fate decision. 2014; 21:1451-1459.
58. Amelio I, Antonov AA, Catani MV, Massoud R, Bernassola F, Knight RA, Melino G and Rufini A. TAp73 promotes anabolism. Oncotarget. 2014; 5:12820-12934. doi: 10.18632/oncotarget.2667.
59. Bunjobpol W, Dulloo I, Igarashi K, Concin N, Matsuo K and Sabapathy K. Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell death and differentiation. 2014; 21:1240-1249.
60. D'Alessandro A, Amelio I, Berkers CR, Antonov A, Vousden KH, Melino G and Zolla L. Metabolic effect of TAp63alpha: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget. 2014; 5:7722-7733. doi: 10.18632/oncotarget.2300.
61. Fatt MP, Cancino GI, Miller FD and Kaplan DR. p63 and p73 coordinate p53 function to determine the balance between survival, cell death, and senescence in adult neural precursor cells. Cell death and differentiation. 2014; 21:1546-1559.
62. Kostecka A, Sznarkowska A, Meller K, Acedo P, Shi Y, Mohammad Sakil HA, Kawiak A, Lion M, Krolicka A, Wilhelm M, Inga A and Zawacka-Pankau J. JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell death & disease. 2014; 5:e1484.
63. Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND and Moll UM. p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. Cell death and differentiation. 2014; 21:645-654.
64. Burnley P, Rahman M, Wang H, Zhang Z, Sun X, Zhuge Q and Su DM. Role of the p63-FoxN1 regulatory axis in thymic epithelial cell homeostasis during aging. Cell death & disease. 2013; 4:e932.
65. Salah Z, Bar-mag T, Kohn Y, Pichiorri F, Palumbo T, Melino G and Aqeilan RI. Tumor suppressor WWOX binds to DeltaNp63alpha and sensitizes cancer cells to chemotherapy. Cell death & disease. 2013; 4:e480.
66. Wu J, Liang S, Bergholz J, He H, Walsh EM, Zhang Y and Xiao ZX. DeltaNp63alpha activates CD82 metastasis suppressor to inhibit cancer cell invasion. Cell death & disease. 2014; 5:e1280.
67. Agostini M, Niklison-Chirou MV, Catani MV, Knight RA, Melino G and Rufini A. TAp73 promotes anti-senescence-anabolism not proliferation. Aging(Albany NY). 2014; 6:921-930.
68. Amelio I, Cutruzzola F, Antonov A, Agostini M and Melino G. Serine and glycine metabolism in cancer. Trends in biochemical sciences. 2014; 39:191-198.
69. Amelio I and Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends in biochemical sciences. 2015; 40:425-434.
70. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP, Mak TW, Melino G and Simon HU. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell death and differentiation. 2013; 20:1415-1424.
71. Inoue S, Tomasini R, Rufini A, Elia AJ, Agostini M, Amelio I, Cescon D, Dinsdale D, Zhou L, Harris IS, Lac S, Silvester J, Li WY, Sasaki M, Haight J, Brustle A, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:1843-1848.
72. Melino G, Memmi EM, Pelicci PG and Bernassola F. Maintaining epithelial stemness with p63. Science signaling. 2015; 8:re9.
73. Memmi EM, Sanarico AG, Giacobbe A, Peschiaroli A, Frezza V, Cicalese A, Pisati F, Tosoni D, Zhou H, Tonon G, Antonov A, Melino G, Pelicci PG and Bernassola F. p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:3499-3504.
74. Viticchie G, Agostini M, Lena AM, Mancini M, Zhou H, Zolla L, Dinsdale D, Saintigny G, Melino G and Candi E. p63 supports aerobic respiration through hexokinase II. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:11577-11582.
75. Candi E, Agostini M, Melino G and Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Human mutation. 2014; 35:702-714.
76. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M and Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nature cell biology. 2013; 15:991-1000.
77. Amelio I, Inoue S, Markert EK, Levine AJ, Knight RA, Mak TW and Melino G. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1alpha degradation. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:226-231.
78. Moll UM and Slade N. p63 and p73: roles in development and tumor formation. Molecular cancer research. 2004; 2:371-386.
79. Deyoung MP and Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene. 2007; 26:5169-5183.
80. Meyer G, Cabrera Socorro A, Perez Garcia CG, Martinez Millan L, Walker N and Caput D. Developmental roles of p73 in Cajal-Retzius cells and cortical patterning. The Journal of neuroscience. 2004; 24:9878-9887.
81. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000; 404:99-103.
82. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Bruck W and Moll UM. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell death and differentiation. 2010; 17:1816-1829.
83. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD and Mak TW. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes & development. 2010; 24:549-560.
84. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G and Mak TW. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:797-802.
85. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & development. 2008; 22:2677-2691.
86. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ and Karayan-Tapon L. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. British journal of cancer. 2006; 95:1062-1069.
87. Kamiya M and Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. Journal of neuro-oncology. 2002; 59:143-149.
88. Ugur H, Sayan AE, Ozdamar SO, Kanpolat Y and Ozturk M. Expression of TAP73 and DeltaNP73 in malignant gliomas. Oncology reports. 2004; 11:1337-1341.
89. Agostini M, Tucci P, Chen H, Knight RA, Bano D, Nicotera P, McKeon F and Melino G. p73 regulates maintenance of neural stem cell. Biochemical and biophysical research communications. 2010; 403:13-17.
90. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, Velletri T, Tucci P, Sayan BS, Conforti F, Gallagher E, Nicotera P, Mak TW, Melino G, Knight RA and Agostini M. p73: a multifunctional protein in neurobiology. Molecular neurobiology. 2011; 43:139-146.
91. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer cell. 2006; 9:391-403.
92. Lee JK, Joo KM, Lee J, Yoon Y and Nam DH. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. OncoTargets and therapy. 2014; 7:1933-1944.
93. Aybar MJ, Nieto MA and Mayor R. Snail precedes slug in the genetic cascade required for the specification and migration of the Xenopus neural crest. Development. 2003; 130:483-494.
94. Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic acids research. 2011; 39(Web Server issue):W323-327.
95. Friedl P and Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011; 147:992-1009.
96. Mikheev AM, Mikheeva SA, Trister AD, Tokita MJ, Emerson SN, Parada CA, Born DE, Carnemolla B, Frankel S, Kim DH, Oxford RG, Kosai Y, Tozer-Fink KR, Manning TC, Silber JR and Rostomily RC. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy. Neuro-oncology. 2015; 17:372-382.
97. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN and Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nature cell biology. 2015; 17:170-182.
98. Morra L and Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Archiv. 2011; 459:465-475.
99. Takeshita S, Kikuno R, Tezuka K and Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. The Biochemical journal. 1993; 294 :271-278.
100. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF and Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. Journal of bone and mineral research. 1999; 14:1239-1249.
101. Liu AY, Zheng H and Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix biology. 2014; 37:150-156.
102. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012; 481:85-89.
103. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Oshita Y and Morishita R. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. International journal of molecular medicine. 2011; 28:181-186.
104. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G and Di Loreto C. Expression of periostin in human breast cancer. Journal of clinical pathology. 2008; 61:494-498.
105. Takanami I, Abiko T and Koizumi S. Expression of periostin in patients with non-small cell lung cancer: correlation with angiogenesis and lymphangiogenesis. The International journal of biological markers. 2008; 23:182-186.
106. Hong LZ, Wei XW, Chen JF and Shi Y. Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncology letters. 2013; 6:1595-1603.
107. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F and Yuan YZ. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. International journal of oncology. 2009; 34:821-828.
108. Li Z, Zhang X, Yang Y, Yang S, Dong Z, Du L, Wang L and Wang C. Periostin expression and its prognostic value for colorectal cancer. International journal of molecular sciences. 2015; 16:12108-12118.
109. Sablina AA, Chumakov PM and Kopnin BP. Tumor suppressor p53 and its homologue p73alpha affect cell migration. The Journal of biological chemistry. 2003; 278:27362-27371.
110. Zhang Y, Yan W, Jung YS and Chen X. Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition. The Journal of biological chemistry. 2012; 287:17746-17753.
111. Pont LM, Balvers RK, Kloezeman JJ, Nowicki MO, van den Bossche W, Kremer A, Wakimoto H, van den Hoogen BG, Leenstra S, Dirven CM, Chiocca EA, Lawler SE and Lamfers ML. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene therapy. 2015; 22:947-5.
112. Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, Sun C and Xia G. Periostin Mediates TGF-beta-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells. Cellular physiology and biochemistry. 2015; 36:799-809.
113. Liu Y and Liu BA. Enhanced proliferation, invasion, and epithelial-mesenchymal transition of nicotine-promoted gastric cancer by periostin. World journal of gastroenterology. 2011; 17:2674-2680.
114. Sayan AE, Paradisi A, Vojtesek B, Knight RA, Melino G and Candi E. New antibodies recognizing p73: comparison with commercial antibodies. Biochemical and biophysical research communications. 2005; 330:186-193.
115. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, Han YC, Candi E, Knight RA, Mak TW and Melino G. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:21099-21104.
116. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC and Vousden KH. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009; 139:1327-1341.
117. Niklison-Chirou MV, Steinert JR, Agostini M, Knight RA, Dinsdale D, Cattaneo A, Mak TW and Melino G. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:18952-18957.
118. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M and Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21:2933-2942.
119. Amelio I, Gostev M, Knight RA, Willis AE, Melino G and Antonov AV. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell death & disease. 2014; 5:e1051.
120. Celardo I, Grespi F, Antonov A, Bernassola F, Garabadgiu AV, Melino G and Amelio I. Caspase-1 is a novel target of p63 in tumor suppression. Cell death & disease. 2013; 4:e645.
121. Antonov A, Agostini M, Morello M, Minieri M, Melino G and Amelio I. Bioinformatics analysis of the serine and glycine pathway in cancer cells. Oncotarget. 2014; 5:11004-11013. doi: 10.18632/oncotarget.2668.